HEALTHSTAT NEWS
STAT+: Pharmalittle: We’re reading about a Medicare pilot and orphan drugs, Pfizer cutbacks, and more
A Medicare pilot program called GUARD, aimed at lowering drug prices through 'most-favored nation' pricing, could lose significant savings if rare disease drugs are excluded, according to biotech lobbying efforts. Additionally, reports of potential mergers between AstraZeneca and Bristol Myers Squibb have been denied by anonymous sources.
Mentioned
Related Signal
Adjacent reporting
- STAT+: Exemption of rare disease therapies in drug-pricing pilots would wipe out huge savings, analysis finds
- STAT+: Pharmalittle: We’re reading about AstraZeneca-Bristol merger talks, a revised 340B plan, and more
- STAT+: Makers of rare disease drugs seek exemption from Trump’s price-cut pilots
- STAT+: Pharmalittle: We’re reading about a hepatitis B drug, CVS returns Lilly obesity drug to formularies, and more